Accelerated discovery of novel targeted protein degradation therapeutics
As targeted protein degradation continues to evolve as a new therapeutic modality, specialist computational approaches can provide deep insights to ...
We were delighted to welcome Dr Ashraf Zarkan from the Department of Genetics, University of Cambridge to deliver a webinar on 'Discovering a novel therapy for urinary tract infections through outsourcing in-silico drug discovery'.
Serious bacterial infections represent a worldwide threat, due mainly to the emergence of antibiotic-resistant bacteria for which there are limited therapies. Urinary Tract Infections (UTIs) are among the most prevalent bacterial infections, affecting 150 million people per year, with 75% of infections occurring due to uropathogenic E. coli. Research from the University of Cambridge (Dr Ashraf Zarkan & Dr David Summers, Department of Genetics) highlighted the inhibition of an E. coli enzyme as a plausible route to reduce pathogenicity and increase antibiotic effectiveness in UTIs.
Request your webinar recording of 'Discovering a novel therapy for urinary tract infections through outsourcing in-silico drug discovery' to learn how a collaboration between the University of Cambridge and Cresset Discovery that combined cutting edge research with in-silico drug discovery expertise, successfully identified a set of novel inhibitors and, in a proof of concept, confirmed their ability to reduce pathogenicity in clinical strains of uropathogenic E. coli. The current focus is in optimizing these hits and completing pre-clinical development to be able to move further into clinical trials.